JH-RE-06

• Description:

  JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing the recruitment of mutagenic POLζ. JH-RE-06 is an effective REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), which targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 also improves chemotherapy.

• Stability:

  ≥ 2 years

• Purity:

  >98% (HPLC)

• Weight:

  468.72

• Molecular Formula:

  C20H16Cl3N3O4

• Notes:

  Research use only, not for human use.

• Receptor:

  REV1-REV7

• CAS Number:

  1361227-90-8